Effects of Inadequate Amino Acid Mixture Intake on Nutrient Supply of Adult Patients with Phenylketonuria by Hochuli, Michel et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2017
Effects of Inadequate Amino Acid Mixture Intake on Nutrient Supply of
Adult Patients with Phenylketonuria
Hochuli, Michel; Bollhalder, Sandra; Thierer, Carina; Refardt, Julie; Gerber, Philipp; Baumgartner,
Matthias R
Abstract: BACKGROUND Adult phenylketonuria (PKU) patients often reduce their intake of amino
acid mixture (AAM) to less than the prescribed amounts. Effects of reduced AAM intake on nutrient
supply were evaluated. METHODS Nutrient intake was calculated in 20 adult PKU patients based on a
structured food record and complemented by laboratory assessment of nutritional status. Patients were
classified into 2 groups, (A) regular AAM intake, or (B) AAM intake below calculated requirements.
RESULTS Group B consumed a higher proportion of natural protein (60 ± 23 vs. 33 ± 12%, p =
0.002); however, the total protein intake was below the recommended amounts in 60% of patients in
group B versus 7% in group A (p = 0.03). Fat intake was higher in group B (39 ± 9% of energy vs.
31 ± 6%, p = 0.03), mainly from saturated fats. Selenium, folate, and vitamin B12 intake was below
the recommended intake in group B. However, serum concentrations of these analytes remained within
the normal range in both groups, although vitamin B12 levels were lower in group B. Plasma tyrosine
correlated with AAM intake, and hydroxyproline correlated with the amount of natural protein consumed.
CONCLUSION Relaxed AAM intake resulted in insufficient nutrient supply, despite a compensatory
increase in consumption of natural protein. Care needs to be taken to ensure adequate nutrition in
adults with PKU.
DOI: https://doi.org/10.1159/000479746
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-139664
Journal Article
Published Version
Originally published at:
Hochuli, Michel; Bollhalder, Sandra; Thierer, Carina; Refardt, Julie; Gerber, Philipp; Baumgartner,
Matthias R (2017). Effects of Inadequate Amino Acid Mixture Intake on Nutrient Supply of Adult
Patients with Phenylketonuria. Annals of Nutrition Metabolism, 71(3-4):129-135.
DOI: https://doi.org/10.1159/000479746
E-Mail karger@karger.com
 Original Paper 
 Ann Nutr Metab 2017;71:129–135 
 DOI: 10.1159/000479746 
 Effects of Inadequate Amino Acid 
Mixture Intake on Nutrient Supply of 
Adult Patients with Phenylketonuria 
 Michel Hochuli a, c    Sandra Bollhalder a    Carina Thierer a    Julie Refardt d    
Philipp Gerber a    Matthias R. Baumgartner b, c 
 a  Division of Endocrinology, Diabetes, and Clinical Nutrition, University Hospital Zurich, Zurich,  b  Division of 
Metabolism and Children’s Research Center, University Children’s Hospital, Zurich, and  c  Radiz – Rare Disease 
Initiative Zurich, Clinical Research Priority Program for Rare Diseases, University of Zurich,  Zurich , and  d  Clinic of 
Endocrinology, Diabetes and Metabolism, University Hospital Basel,  Basel , Switzerland 
 
group B. Plasma tyrosine correlated with AAM intake, and 
hydroxyproline correlated with the amount of natural pro-
tein consumed.  Conclusion: Relaxed AAM intake resulted in 
insufficient nutrient supply, despite a compensatory in-
crease in consumption of natural protein. Care needs to be 
taken to ensure adequate nutrition in adults with PKU.  
 © 2017 S. Karger AG, Basel 
 Introduction 
 Phenylketonuria (PKU, OMIM 261600) is an inherit-
ed disorder of phenylalanine metabolism. PKU results 
from a genetic defect of the enzyme phenylalanine hy-
droxylase, which converts phenylalanine (Phe) to tyro-
sine as the first step of the Phe degradation pathway  [1, 
2] . Newborn screening for PKU with the early introduc-
tion of dietary therapy has been a great success, prevent-
ing the severe neurological damage that occurs in chil-
dren with high Phe levels when PKU is left untreated. In 
dietary treatment of PKU, natural protein intake is re-
stricted (low-Phe diet), and a Phe-free amino acid mix-
ture (AAM) is supplemented to ensure adequate protein 
supply  [3] . Trace elements, minerals, and vitamins are 
added to the AAM to compensate for nutritional imbal-
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 Abstract 
 Background: Adult phenylketonuria (PKU) patients often re-
duce their intake of amino acid mixture (AAM) to less than 
the prescribed amounts. Effects of reduced AAM intake on 
nutrient supply were evaluated.  Methods: Nutrient intake 
was calculated in 20 adult PKU patients based on a struc-
tured food record and complemented by laboratory assess-
ment of nutritional status. Patients were classified into 
2 groups, (A) regular AAM intake, or (B) AAM intake below 
calculated requirements.  Results: Group B consumed a high-
er proportion of natural protein (60 ± 23 vs. 33 ± 12%,  p = 
0.002); however, the total protein intake was below the rec-
ommended amounts in 60% of patients in group B versus 7% 
in group A ( p = 0.03). Fat intake was higher in group B (39 ± 
9% of energy vs. 31 ± 6%,  p = 0.03), mainly from saturated 
fats. Selenium, folate, and vitamin B12 intake was below the 
recommended intake in group B. However, serum concen-
trations of these analytes remained within the normal range 
in both groups, although vitamin B12 levels were lower in 
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ances resulting from dietary restrictions  [4] . The amount 
of natural protein allowed in the diet depends on the re-
sidual enzyme activity and the defined plasma Phe con-
centration target. Strict control of Phe levels is manda-
tory in childhood and early adolescence to ensure normal 
development and to avoid neurological damage, as well 
as in pregnancy to prevent Phe fetopathy. For adults, cur-
rent guidelines recommend life-long dietary treatment 
 [5, 6] . National recommendations regarding the upper 
target blood Phe concentration for adults outside preg-
nancy are somewhat heterogeneous. The advised upper 
limit in Switzerland is 600 μmol/L, which is in accordance 
with the recently published European guideline  [6] . How-
ever, many patients with good Phe control in childhood 
and adolescence will have difficulties to maintain a rigid 
diet in adulthood  [7–10] . Adults often find it difficult to 
integrate a strict diet, including regular AAM intake, into 
social and professional life. They frequently relax their 
protein-restricted diet and reduce AAM intake below 
prescribed amounts. Commonly, patients maintain their 
habitual dietary practices with a variable degree of natural 
protein restriction despite relaxed AAM intake, which 
constitutes a risk for nutritional imbalances and deficien-
cies  [11, 12] . In the present prospective cross-sectional 
study, eating habits, nutritional status, and selected nutri-
tional biomarkers were evaluated in a cohort of adult 
PKU patients, in relation to their treatment compliance 
regarding AAM intake. 
 Materials and Methods 
 Study Design  
 This study was planned in a prospective cross-sectional design. 
Patients with classical or moderate PKU were recruited during a 
regular consultation in the outpatient clinics of the University 
Hospitals of Zurich and Basel. Study participants were asked to fill 
in a questionnaire about current modalities and frequency of AAM 
intake, and were asked to provide a detailed 4-day food record 
within 4 weeks after the consultation when recruited for the study. 
Anthropometric measurements and laboratory assessment were 
done as part of standard medical care on the occasion of this con-
sultation. Laboratory testing included biochemical parameters, 
such as creatinine, C-reactive protein, albumine, prealbumine, se-
lected minerals and trace elements (ferritin, selenium, zinc), vita-
mins (vitamin B12, folic acid, 25-OH vitamin D), as well as a com-
plete plasma amino acid profile. Amino acid profiles were mea-
sured from heparin plasma by ion-exchange high-performance 
liquid chromatography. Venous blood samples were collected in 
the non-fasting state prior to the next main meal (mainly before 
lunch), 3–4 h after the last AAM intake, according to the typical 
clinical routine in the outpatient department. All procedures fol-
lowed were in accordance with the ethical standards of the respon-
sible committee on human experimentation (registration number 
KEK ZH 2013-0120) and with the Helsinki Declaration of 1975 as 
revised in 2000. The study was registered at the database Clinical-
Trials.gov (NCT01879995). 
 Patients and Methods/Study Groups 
 Male or female patients with classical or moderate PKU aged 
>18 years and willing to provide a detailed food record were eli-
gible for the study. None of the patients was on a treatment with 
sapropterin (BH4). Twenty-four patients (17 classical, 7 moderate 
PKU, 14 male, 10 female) were recruited, 21 patients from the out-
patient clinic in Zurich, and 3 from Basel. All patients participating 
in the study returned the food records and questionnaires. Patients 
were classified into 2 groups, (A) regular AAM intake (i.e., total 
daily amount of AAM according to prescription, taken in 2 or 
3 portions per day) and (B) AAM intake below recommendations. 
This classification was based on the patient interview at the time 
of recruitment (when blood sampling was done), as well as on the 
information obtained from the individual study questionnaires 
filled in after this consultation. Answers in the questionnaires were 
checked for consistency with the patient interview and medical 
history. Patients were instructed not to change dietary habits be-
tween the consultation and the time when food intake was record-
ed. Four patients with moderate PKU had a Phe tolerance high 
enough to reach blood Phe levels <600 μmol/L without requiring 
any AAM to cover their protein needs. These 4 patients were omit-
ted from these 2 groups, but the data were used for the correlation 
of natural protein intake with plasma hydroxyproline concentra-
tions. Informed consent was obtained from all patients for being 
included in the study. The first patient was recruited in June 2013 
and the last in February 2015. 
 Assessment of Nutrient Intake  
 Nutrient intake was calculated based on a detailed 4-day diet 
record including the type and quantity of all foods, beverages, and 
the AAM taken within 4 consecutive days. Whenever possible, the 
quantity of food was weighed by the patients, using a digital kitch-
en scale. One of the 4 protocolled days was required to be a week-
end day, and the other 3 days weekdays. Patients were asked to 
send in a dried blood card for measurement of Phe after comple-
tion of the food record. Macro- and micronutrient intake was cal-
culated based on the food records, using the Food Control 
 Management System “DIÄT-2000” software (Soft&Hard, D. 
 Beyer)  [12] . Reference values for nutrient intake were based on the 
2015 D-A-CH recommendations  [13] . Recommended protein in-
take, including AAM, was calculated according to the D-A-CH 
reference value for adults (0.8 g/kg body weight), with an empirical 
increment of +10%. This empirical increment corresponded to the 
usual practice of establishing dietary treatment plans in the par-
ticipating clinics at the time when this study was conducted. Pa-
tients were allowed animal protein according to their individual 
Phe tolerance and as long as Phe values were well controlled.
 Statistics 
 Data are presented as arithmetic means with SD or ranges. Sta-
tistical analysis was performed using the statistical package SPSS 
22 (IBM SPSS Statistics). A 2-sided value of  p < 0.05 was considered 
significant. For comparison of continuous variables between 
groups, an independent samples  t -test or one-way analysis of vari-
ance was applied. Phe values of individual patients were compared 
using paired  t -tests. Non-normally distributed data were log-
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transformed prior to statistical testing. Fisher’s exact test was used 
to compare categorical variables presented as percentages. One-
way analysis of variance with linear contrast was used to test for a 
linear trend of hydroxyproline or tyrosine concentrations across 
categories of natural protein or AAM intake. Post-hoc Bonferroni 
correction was applied to account for multiple comparisons.
 Results 
 The present analysis is based on a cohort of 20 PKU 
patients, 15 were allocated to group A (regular AAM in-
take, i.e., a total daily amount of AAM according to pre-
scription, taken in 3 or fewer of portions per day) and 5 to 
group B (AAM intake below the prescribed amount). The 
mean age was 32 ± 12 years in group A (median 31 years, 
range 18–64 years) and 39 ± 8.4 years in group B (median 
39 years, range 30–50 years; ns). Group B had a higher 
proportion of males (47% group A, 80% group B), albeit 
not statistically significant. Body mass index was signifi-
cantly lower in group B with irregular AAM intake (body 
mass index: group A 24.6 ± 4.3 kg/m 2 , group B 20.6 ± 
2.1 kg/m 2 ,  p = 0.04), although total energy intake during 
the protocolled period was similar in both groups (see 
below).  The plasma Phe concentration at the time of the 
consultation (measured as part of the complete plasma 
amino acid profile by ion-exchange high-performance 
liquid chromatography) was somewhat above the recom-
mended upper target in Switzerland of 600 μmol/L, with 
a statistically nonsignificant trend toward higher Phe val-
ues in the group with irregular AAM intake (group A 
650 ± 283, group B 760 ± 350 μmol/L; ns). Plasma Phe 
values of individual patients were similar to the values 
obtained in the previous and subsequent consultations. 
Phe values measured from dried blood spots after the 
completion of the food records (where available) were not 
significantly different from the Phe values measured from 
dried blood spots sent in by patients during the year be-
fore they were recruited for the study. The median time 
interval between the consultation when laboratory assess-
ment was performed and keeping the food record was 
8.5 days. Reported Phe tolerance based on pediatric med-
ical charts was similar in both groups (group A 493 ± 
183 mg, group B 450 ± 218 mg; ns). However, this value 
was not available for all study participants. 
 Nutrient Intake and Laboratory Assessment 
 The prescribed daily amount of protein from AAM 
was 0.73 ± 0.2 g/kg body weight for group A and 0.68 ± 
0.2 g/kg for group B. The effective mean daily AAM intake 
was equal to the prescribed amount in group A, whereas 
AAM intake in group B corresponded to approximately 
half the prescribed amount (A 0.73 ± 0.1 g/kg vs. B 0.38 ± 
0.3 g/kg protein from AAM,  p = 0.001;  Fig. 1 ). The pre-
scribed AAM were balanced medical PKU products com-
mercially available in Switzerland, mainly concentrated 
amino acid powders (P-AM 3 [Nutricia GmbH], 14 pa-
tients.  Milupa PKU 3 [Nutricia GmbH], 3 patients. Mi-
lupa PKU 3-advanta [Nutricia GmbH], 2 patients. XPhe 
smart A [metaX], 1 patient). A few patients replaced single 
portions of the amino acid powder by portioned or ready-
to-drink AAM products (P-AM Anamix [Nutricia 
GmbH], 1 patient. PKU Lophlex LQ 20 [Nutricia GmbH], 
1 patient). There were no relevant differences between the 
2 groups with respect to the type and composition of the 
prescribed AAMs. The daily amount of AAM was taken 
on average in 2.6 portions per day (range 2.0–3.0) in group 
A vs. 1.4 portions per day (range 0–2.0) in group B. Al-
though the consumption of natural protein (percent of 
total protein intake) was higher in group B with irregular 
AAM intake (60 ± 23 vs. 33 ± 12%,  p = 0.002), the total 
protein intake was below the recommended intake in 60% 
of patients in group B versus 7% in group A ( p = 0.03). The 
mean deviation of protein intake from the reference value 
was + 31.1 ± 27% in group A vs. –0.72 ± 35% in group B 
( p = 0.02). Daily energy intake was not significantly differ-
ent between both groups (group A: 2167 kcal/day, 32 kcal/
kg/day. Group B 2272 kcal/day, 38 kcal/kg/day; ns). How-
ever, patients with irregular AAM intake consumed a 
higher proportion of fat (39 ± 9 vs. 31 ± 6% of total energy 
intake,  p = 0.03), mainly from saturated fats (intake 33.3 ± 
13 vs. 20.9 ± 7.8 g,  p = 0.017). The intake of monounsatu-
rated and essential fatty acids was not significantly differ-
ent between groups. Carbohydrate intake was equal in 
both groups (52% of total energy). 
 Supply of calcium, vitamin B12, folate, selenium, and 
zinc was significantly lower in the group with irregular 
AAM intake, but only selenium, folate, and vitamin B12 
intake was clearly below the recommended intake quan-
tity ( Fig. 2 ). However, despite lower intake, mean serum 
concentrations of these analytes remained within the nor-
mal range in both groups, although vitamin B12 levels 
were significantly lower in group B but still within normal 
limits ( Table  1 ). All plasma amino acid concentrations 
remained within the normal range in both groups, al-
though many patients in group B had a protein intake 
below the recommended intake ( Table  2 ). There was, 
however, a trend toward lower concentrations of branched 
chain amino acids in group B (not significant). Glutamine 
was significantly lower in group A. Tyrosine (i.e., the 
product of the deficient enzyme) was lower in group B. 
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 Fig. 1. Macronutrient intake. Protein intake from amino acid mix-
ture (AAM;  a ), natural protein intake (absolute amount, and in 
percent of total protein intake;  b ,  d ), total protein intake (from 
AAM and natural protein, absolute amount and as percent devia-
tion from the recommended intake;  c ,  e ), according to treatment 
compliance regarding AAM intake. The mean daily AAM intake 
of group B corresponds to approximately half the amount of group 
A. Despite a compensatory increase in consumption of natural 
protein, the majority (60%) of patients in group B had a total pro-
tein intake below the recommended intake. Fat intake was higher 
in group B, mainly from saturated (animal) fats ( f ).  *  Significantly 
different ( p < 0.05). Box and whiskers plots with bars representing 
minimum to maximum values.  
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Plasma tyrosine concentrations related to the amount of 
AAM consumed ( Fig. 3 ). There was a clear association of 
plasma hydroxyproline concentrations with the propor-
tion of natural protein in the diet ( Fig. 3 ). 
 Discussion 
 This study shows that adult PKU patients who relax 
their intake of AAM have a distinct dietary pattern, with an 
increased intake of saturated fats and insufficient supply of 
protein, vitamin B12, and selenium compared to patients 
with regular AAM intake. Patients with lower AAM intake 
consumed more natural protein, but this did not fully com-
pensate for the lower supply from the AAM. The higher fat 
consumption (mainly saturated fats) in the group with ir-
regular AAM intake may be attributed to a higher con-
sumption of animal protein (meat and dairy products).
 All measured analytes (e.g., vitamins, minerals, trace 
elements) and plasma amino acids except for Phe re-
mained within the normal range in both groups, although 
many patients in the group with irregular AAM intake 
had a protein intake and nutrient supply below the rec-
Folic acid
Vitamin B12
Vitamin B6
Selenium
Zinc
Iron
Calcium
–200 –100 0 100
Nutrient intake
(% deviation from reference)
200
Regular (A)
Irregular (B)
300 400
 Fig. 2. Intake of selected minerals, trace elements, and vitamins. 
Supply of calcium, vitamin B12, folate, selenium, and zinc was sig-
nificantly lower in the group with irregular amino acid mixture 
intake, but only selenium, folate, and vitamin B12 intake was clear-
ly below the recommended intake. Nutrient intake is presented as 
percent deviation from the recommended intake. Tukey box and 
whiskers plot.  *  Significantly different ( p < 0.05).  
Table 1.  Selected laboratory parameters
 Group (AAM intake) Normal range
regular ( A) irregular (B)
Folic acid 98±290 14±3 >4 μg/L
Vitamin B12 540±208ǂ 251±75ǂ 180–914 ng/L
Selenium 0.79±0.20 0.94±0.40 0.8–1.1 μmol/L
Zinc 11.2±2.2 11.8±1.5 9–21 μmol/L
Ferritin 78±76 92±52 15–400 μg/L
25-OH vitamin D 34±10 31±12 >20 μg/L
Albumin 45±6 49 40–49 g/L
Prealbumine 295±40 345±74 200–400 mg/L
Creatinine 71±12 82±25 44–106 μmol/L
C-reactive protein 1.9±2 0.3±0.4 <5 mg/L
 Values are given as mean ± SD.
ǂ Significantly different between groups.
Table 2.  Plasma amino acid concentrations
 Group (AAM intake) Normal range, 
μmol/Lreg ular (A) irregular (B)
Alanine 389±61 418±149 192–508
Arginine 48±25 46±26 45–125
Aspartic acid 10±7 8±5 4–28
Asparagine 38±13 44±7 32–64
Glutamic acid 63±37 64±50 11–59
Glutamine 479±75ǂ 593±58ǂ 396–740
Glycine 233±50 341±140 148–324
Histidine 77±13 75±4 58–106
Isoleucine 58±20 44±12 38–94
Leucine 101±32 82±19 76–168
Lysine 165±34 136±23 105–221
Methionine 19±5 17±4 16–36
Phenylalanine 649±283 760±352 38–78
Proline 181±42 201±52 75–307
Serine 94±15 111±21 75–175
Threonine 127±29 104±27 72–192
Tryptophane 36±8 29±4 27–75
Tyrosine 72±24ǂǂ 42±17ǂ 40–92
Valine 274±68 221±50 142–278
 Values are given as means ± SD.
ǂ Significantly different between groups.
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ommended intake. However, some analytes in this group 
were significantly lower (e.g., vitamin B12, tyrosine), or 
showed a trend toward lower values (such as branched 
chain amino acids), although still remaining within the 
normal range. It is expected that these parameters may 
fall below the normal ranges in patients who consistently 
follow a rigid protein-restricted diet combined with very 
low AAM intake. Patients with irregular AAM intake par-
ticipating in this study, however, largely continued AAM 
intake, albeit at lower than prescribed doses. Nonetheless, 
the observed trends indicate that these patients clearly are 
at risk for nutrient deficiencies  [14, 15] . Therefore, regu-
lar follow-up with careful nutritional assessment by a spe-
cialised dietician is mandatory. Ordering of laboratory 
tests should be tailored according to the nutritional as-
sessment, more extensive laboratory testing being justi-
fied in patients with poor treatment compliance (irregu-
lar AAM intake). Vitamin B12 deficiency may be the most 
frequent and relevant deficit in patients who relax their 
AAM intake  [16] . 
 Tyrosine as the product of the deficient enzyme phe-
nylalanine hydroxylase becomes an essential amino acid 
in PKU  [17] . For this reason, AAM are fortified with ty-
rosine. Accordingly, plasma tyrosine was significantly 
lower in patients with irregular AAM intake. Plasma ty-
rosine may, therefore, be used as a marker to estimate 
AAM intake. 
 Plasma hydroxyproline concentrations correlated 
with natural protein intake, as dietary hydroxyproline 
mainly derives from hydrolysed collagen products in an-
imal protein (including gelatine products). Therefore, 
plasma hydroxyproline may represent a biomarker for es-
timating adherence to the protein-restricted diet, at least 
in patients who do not remain on a strict vegetarian (or 
vegan like) diet. Accordingly, plasma glutamine levels 
were higher in group B, consuming higher amounts of 
natural protein. Meat products and eggs are relevant 
sources of dietary glutamine  [18] . Hydroxyproline also 
represents a bone resorption marker, which in theory 
may confound the association with natural protein in-
take. However, it is unlikely that bone resorption will be 
a major confounding factor in the present group of pa-
tients, as we would not expect relevant variations in bone 
resorption in adults with mature skeleton and premeno-
pausal females. Other bone resorption markers such as 
carboxy-terminal collagen (CTX) crosslinks were not 
routinely measured. The value of hydroxyproline as a bio-
marker for natural protein intake will need to be validat-
ed in further studies. 
 This study represents the typical situation and real-life 
setting of an adult PKU clinic, where many patients who 
stay in regular follow-up principally remain on treat-
ment, but relax their diet (restriction of natural protein, 
AAM intake) to a variable degree  [8, 9] . Commonly, pa-
tients reduce the amount of AAM, but maintain some 
dietary protein restriction. This behavior puts patients at 
risk for nutritional deficiencies and imbalances. In this 
study, this is demonstrated for the group of patients with 
inadequate AAM intake. Although patients in this group 
are less adherent to treatment, they are not completely 
off-diet, and still achieve reasonable metabolic control in 
terms of Phe concentrations. However, even patients in 
the group with regular AAM intake on average have Phe 
values somewhat above the recommended target in Swit-
zerland, which illustrates the common problem that even 
adults with good treatment adherence will often struggle 
to maintain a rigid protein-restricted diet to reach recom-
mended Phe targets. Even in the group with good compli-
ance (group A), many patients take the total AAM dose 
in 2 portions daily instead of 3 as recommended. None-
theless, they achieved sufficient nutrient supply as long as 
the total daily amount of AAM was adequate. No differ-
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 Fig. 3. Plasma hydroxyproline and natural 
protein intake. The concentration of hy-
droxyproline in plasma increases with the 
proportion of natural protein in the diet 
( p  = 0.005 for trend;  a ). Plasma tyrosine in-
creases with the amount of amino acid 
mixture consumed ( p = 0.004 for trend;  b ). 
 * *  Significant differences between catego-
ries ( p < 0.05 after Bonferroni correction). 
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ences in nutrient supply and the examined laboratory pa-
rameters were found in patients taking their AAM in 2 
portions daily when compared to patients with 3 portions 
daily (data not shown). 
 Limitations of this study are the small group sizes, es-
pecially for the group with irregular AAM intake. Some 
of the trends observed may have reached significance 
with larger group sizes. Patients with better adherence to 
the treatment regimen in general were easier to motivate 
for study participation, which is a common problem in 
clinical studies. 
 In conclusion, this study demonstrates that patients who 
lower their AAM intake are at risk for nutritional deficien-
cies and have distinct dietary patterns compared to patients 
who follow the prescriptions more strictly. This underlines 
the importance of a regular medical and nutritional assess-
ment, support, and long-term follow-up of adults with 
PKU in dedicated centers for metabolic disorders. 
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